Research Journal of Medical Sciences
ISSN: Online 1993-6095ISSN: Print 1815-9346
Abstract
Patients with chronic kidney disease (CKD) should be particularly concerned about anaemia, especially iron deficiency, as it is a reflection of the disease's prognosis. There are currently few guidelines for treating anaemia in these patients with intravenous iron (IV) therapy. In patients with chronic renal disease, this study compares oral and intravenous iron. In this prospective case‐control research, patients with chronic renal disease who were hospitalized to the medicine department of Sree Mookambika Institute of Medical Sciences, Padanilam, Kulasekharam, Kanyakumari in India. 150 patients in all were split into two groups of 75, one of which received intravenous iron (IV iron sucrose) and the other oral iron (ferrous sulphate 325 mg tablets). In both categories, there were more males (57.6%, 64.7%) than girls (42.3%, 35.2%). In both the IV iron group (33) and the oral iron group (36), the majority of participants were between the ages of 41 and 60. In the IV and oral iron groups, 25.8%, 52.9%, 21.1% and 21.3% of the participants, respectively, had mild, moderate and severe hemoglobin deficiency. When it comes to the measure of iron deficiency anaemia, IV iron sucrose therapy has been shown to be more successful, well‐tolerated and efficacious than oral iron treatment in individuals with chronic renal disease.
How to cite this article:
Megha R. Raju and R.V. Mookambika. Comparing the Effectiveness of Intravenous vs Oral Iron Therapy in Patients with Chronic Kidney Disease: Associated Anemia.
DOI: https://doi.org/10.36478/10.36478/makrjms.2024.11.130.135
URL: https://www.makhillpublications.co/view-article/1815-9346/10.36478/makrjms.2024.11.130.135